One more pharma company reacting to the changing the DNA biotech sector continues it's rapid and steady growth, big pharma continues to shift it's directions and marketing as well...sequencing is going to play a big roll soon and is destined to take much of the 'hit and miss' from how medications are prescribed today...BD  

The healthcare giant yesterday notified employees it will consolidate the sales and marketing operations of two subsidiaries, Ortho Biotech and Centocor, leading to roughly 400 job cuts nationwide, The Star-Ledger of New Jersey reports.

The move is a response to the declining sales of its Procrit anemia med, a spokesman tells the paper. Procrit scrips fell sharply last year after the FDA issued new safety warnings, which were also placed on anemia meds sold by Amgen.

Pharmalot » Johnson & Johnson Cuts Another 400 Jobs


Post a Comment

Google Analytics Alternative